Notice of Proposed Sale · 144
Ascendis Pharma A/S
ASNDNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Ascendis Pharma A/S
- Issuer CIK
- 0001612042
- SEC file number
- 001-36815
- Phone
- 45 70 22 22 44
- Person for whose account securities are to be sold
- HOLTUG LARS
- Relationships to issuer
- Director
- Street
- TUBORG BOULEVARD 12
- City
- HELLERUP
- State / country code
- G7
- Postal code
- DK2900
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| ORDINARY SHARES | 236 | 62,334.59 | 61,977,408 | 09/02/2026 | NASDAQ | CITIGROUP GLOBAL MARKETS |
Broker / market maker — proposed row 1, entry 1
- Name
- CITIGROUP GLOBAL MARKETS
- Street
- 390 GREENWICH ST
- City
- NEW YORK
- State / country code
- NY
- Postal code
- 10013
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| ORDINARY SHARES | 03/02/2026 | SHARE PLAN ACCOUNT | ASCENDIS PHARMA A/S | 236 | N | 03/02/2026 | COMPENSATION |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
SECTION 3 D IS BASED ON INDICATIVE MARKET PRICE 264.1296. UNDER SECURITIES TO BE SOLD DATE ACQUIRED ARE VARIOUS. SALE OF SHARES TO COVER INCOME TAX
Notice signature
- Notice date
- 09/02/2026
- Signed
- CONFORMED SIGNATURE ON FILE
Company context
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.